Prostamax is strictly for laboratory research and is commonly employed in the following investigational areas:

Prostate Health and Chronic Prostatitis

Research models utilize Prostamax to evaluate its efficacy in the management of prostate dysfunction. Investigations focus on the peptide’s anti-inflammatory properties, quantifying changes in tissue morphology and cellular recovery in experimental models of chronic aseptic prostatitis and its associated complications.

Epigenetics and Chromatin Reactivation

Experimental protocols employ this tetrapeptide to characterize its direct interactions with human DNA. Studies assess its influence on lymphocyte heterochromatin in situ, specifically measuring its ability to induce the decondensation (unrolling) of chromatin and reactivate ribosomal genes in senile subjects or aging cellular models.

Immune Modulation and Secretory Function

In immunological and gerontological research, Prostamax is used to study the broader peptide bioregulation of the immune system. Researchers evaluate how it affects the state of secretory immunity (e.g., in the saliva of elderly patients) and alters epigenetic controls to optimize lymphocyte function.

Pathway / Mechanistic Context

The primary mechanism of action for Prostamax in research settings involves its function as an epigenetic regulator and intracellular signaling molecule.

• Cellular Transport and Nuclear Penetration: Utilizes membrane peptide transport systems (such as LAT and PEPT family transporters) to bypass the cellular membrane and enter the nucleus.
• Chromatin Decondensation: Interacts directly with DNA and histones to induce deheterochromatinization, unrolling tightly packed heterochromatin to make genetic information accessible.
• Gene Activation and Tissue Repair: Activates ribosomal genes and stimulates targeted protein synthesis, which subsequently reduces inflammation, promotes cellular longevity, and supports structural recovery in the prostate and immune cells.

Preclinical Research Summary

Published preclinical literature documents investigations of Prostamax across diverse experimental models focusing on epigenetics, prostate health, and aging.

• In urological models, experimental studies of Prostamax demonstrated significant efficiency in the therapy of chronic aseptic prostatitis, reducing inflammation and supporting tissue recovery.
• In vitro gerontological studies utilizing human lymphocytes from senile subjects showed that Prostamax induces the reactivation of chromatin and activates ribosomal genes.
• Computational and in vitro research on cellular transport mechanisms confirmed the feasibility of transporting biologically active ultrashort peptides like Prostamax via LAT and PEPT family solute carriers.
• Clinical-translational observations indicate that peptide bioregulation effectively modulates secretory immunity and supports structural homeostasis in aging cohorts with conditions like chronic generalized periodontitis.

Form & Analytical Testing

• Solid-Phase Peptide Synthesis
• Lyophilization
• Identity Verification: Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the purity standard.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• V. K. Khavinson, N. S. Linkova, A. I. Rudskoy, and M. G. Petukhov, “Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters,” MDPI AG, Mar. 2023. doi: 10.3390/biom13030552. https://doi.org/10.3390/biom13030552
• T. G. Borovskaya et al., “Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications,” Scientific Research Publishing, Inc., 2013. doi: 10.4236/mri.2013.23007. https://doi.org/10.4236/mri.2013.23007
• T. Meskhi et al., “[The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ].,” Biofizika, vol. 49 6, pp. 1091–3, 2004.
• V. Kh. Khavinson, T. A. Lezhava, and V. V. Malinin, “Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects,” Springer Science and Business Media LLC, Jan. 2004. doi: 10.1023/b:bebm.0000024393.40560.05. https://doi.org/10.1023/b:bebm.0000024393.40560.05
• T. Lezhava, J. Monaselidze, T. Kadotani, N. Dvalishvili, and T. Buadze, “Anti-aging peptide bioregulators induce reactivation of chromatin.,” Georgian medical news, vol. 133, pp. 111–5, 2006.
• N. N. Bedelov, A. K. Iordanishvili, M. E. Malyshev, M. A. Vasiliev, and K. A. Kerimhanov, “Effect of Peptide Bioregulation on the State of Secretory Immunity in the Saliva of Elderly Patients with Chronic Generalized Periodontitis,” Pleiades Publishing Ltd, Apr. 2021. doi: 10.1134/s2079057021020041. https://doi.org/10.1134/s2079057021020041
• V. Khavinson, N. Linkova, A. Diatlova, and and A. Dudkov, “Peptide regulation of plant cells differentiation and growth,” EDP Sciences, 2024. doi: 10.1051/bioconf/20248202003. https://doi.org/10.1051/bioconf/20248202003

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.